Intraspinal application of endothelin results in focal ischemic injury of spinal gray matter and restricts the differentiation of engrafted neural stem cells.
Previous data have shown that pluripotent stem cells engrafted into the contused spinal cord differentiate only along an astrocytic lineage. The unknown restrictive cues appear to be quite rigid as even neuronal-restricted precursors fail to differentiate to the mature potential they exhibit in vitro after similar grafting into the contused spinal cord. It has been hypothesized that this potent lineage restriction is, in part, the result of the significant loss of both gray and white matter observed following spinal contusion, which elicits a massive acute inflammatory response and is manifested chronically by dramatic cystic cavitation. To evaluate the gray matter component, we developed a clinically relevant model of focal gray matter ischemic injury using the potent vasoconstrictor endothelin (ET-1) and characterized the differentiation of pluripotent stem cells transplanted into this atraumatic vascular SCI. Results demonstrate that low dose ET-1 microinjection into cervical spinal gray matter results in an inflammatory response that is temporally comparable to that observed following traumatic SCI, as well as chronic gray matter loss, but without significant cystic cavitation or white matter degeneration. However, despite the preservation of host spinal parenchyma, no elaboration of neuronal phenotypes was observed from engrafted stem or precursor cells. These results suggest that a common pathologic component responsible for this lineage restriction exists between contusive SCI and ET-1 mediated focal ischemic SCI.
Benton
Richard L
RL
Kentucky Spinal Cord Injury Research Center (KSCIRC), 511 South Floyd Street, MDR 616, Louisville, KY 40292, USA.
Woock
John P
JP
Gozal
Evelyne
E
Hetman
Michal
M
Whittemore
Scott R
SR
D000818:Animals; D001483:Base Sequence; D002454:Cell Differentiation / Q000187:drug effects*; D017931:DNA Primers; D019332:Endothelin-1 / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D007278:Injections, Spinal; D008845:Microinjections; D009474:Neurons / Q000166:cytology / Q000187:drug effects*; D039904:Pluripotent Stem Cells / Q000166:cytology / Q000187:drug effects*; D051381:Rats; D011916:Rats, Inbred F344; D013119:Spinal Cord Injuries / Q000139:chemically induced* / Q000473:pathology; D033581:Stem Cell Transplantation
D017931:DNA Primers; D019332:Endothelin-1